[1]
|
Ogurtsova, K., Da Rocha Fernandes, J.D., Huang, Y., et al. (2017) IDF Diabetes Atlas: Global Estimates for the Preva-lence of Diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50.
https://doi.org/10.1016/j.diabres.2017.03.024
|
[2]
|
Munk, M.R., Somfai, G.M., de Smet, M.D., et al. (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International Journal of Mo-lecular Sciences, 23, 7585.
https://doi.org/10.3390/ijms23147585
|
[3]
|
Parravano, M., Costanzo, E. and Querques, G. (2020) Profile of Non-Responder and Late Responder Patients Treated for Diabetic Macular Edema: Systemic and Ocular Factors. Acta Diabetologica, 57, 911-921.
https://doi.org/10.1007/s00592-020-01496-7
|
[4]
|
史雪辉, 张丛, 魏文斌. 关注糖尿病黄斑水肿的光学相干断层扫描分型及相关影像特征[J]. 中华眼科医学杂志(电子版), 2021, 11(1): 1-7.
|
[5]
|
Vujosevic, S., Toma, C., Villani, E., et al. (2020) Diabetic Macular Edema with Neuroretinal Detachment: OCT and OCT-Angiography Biomarkers of Treatment Response to Anti-VEGF and Steroids. Acta Diabetologica, 57, 287-296.
https://doi.org/10.1007/s00592-019-01424-4
|
[6]
|
Sun, J.K., Lin, M.M., Lammer, J., et al. (2014) Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes with Center-Involved Diabetic Macular Edema. JAMA Ophthalmology, 132, 1309-1316.
https://doi.org/10.1001/jamaophthalmol.2014.2350
|
[7]
|
Hammes, H.P. (2018) Diabetic Retinopathy: Hypergly-caemia, Oxidative Stress and Beyond. Diabetologia, 61, 29-38.
https://doi.org/10.1007/s00125-017-4435-8
|
[8]
|
Brownlee, M. (2001) Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature, 414, 813-820.
https://doi.org/10.1038/414813a
|
[9]
|
Diabetic Retinopathy Clinical Research Network; Wells, J.A., Glassman, A.R. and Ayala, A.R. (2015) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. The New England Journal of Medicine, 372, 1193-1203.
https://doi.org/10.1056/NEJMoa1414264
|
[10]
|
Bressler, N.M., Varma, R., Suñer, I.J., et al. (2014) Vision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema: Results from RIDE and RISE. Ophthalmology, 121, 2461-2472.
https://doi.org/10.1016/j.ophtha.2014.07.008
|
[11]
|
Ehlers, J.P., Yeh, S. and Maguire, M.G. (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology, 129, 88-99.
https://doi.org/10.1016/j.ophtha.2021.07.009
|
[12]
|
Haritoglou, C., Maier, M., Neubauer, A.S., et al. (2020) Current Concepts of Pharmacotherapy of Diabetic Macular Edema. Expert Opinion on Pharmacotherapy, 21, 467-475. https://doi.org/10.1080/14656566.2020.1713093
|
[13]
|
Browning, D.J., Stewart, M.W. and Lee, C. (2018) Diabetic Macular Edema: Evidence-Based Management. Indian Journal of Ophthalmology, 66, 1736-1750. https://doi.org/10.4103/ijo.IJO_1240_18
|
[14]
|
Roh, M.I.M., Kim, H.S.M., Song, J.H.M., et al. (2009) Effect of In-travitreal Bevacizumab Injection on Aqueous Humor Cytokine Levels in Clinically Significant Macular Edema. Oph-thalmology (Rochester, Minn.), 116, 80-86.
https://doi.org/10.1016/j.ophtha.2008.09.036
|
[15]
|
Dysli, M., Ruckert, R. and Munk, M.R. (2019) Differentiation of Underlying Pathologies of Macular Edema Using Spectral Domain Optical Coherence Tomography (SD-OCT). Ocular Immunology and Inflammation, 27, 474-483.
https://doi.org/10.1080/09273948.2019.1603313
|
[16]
|
Ceklic, L., Huf, W., Ebneter, A., et al. (2019) The Impact of Ganglion Cell Layer Cysts in Diabetic Macular Oedema Treated with Anti-Vascular Endothelial Growth Factor. Acta Ophthalmologica (Oxford, England), 97, e1041-e1047.
https://doi.org/10.1111/aos.14137
|
[17]
|
Yanoff, M., Fine, B.S., Brucker, A.J., et al. (1984) Pathology of Human Cystoid Macular Edema. Survey of Ophthalmology, 28, 505. https://doi.org/10.1016/0039-6257(84)90233-9
|
[18]
|
Karst, S.G., Lammer, J. and Mitsch, C. (2018) Detailed Anal-ysis of Retinal Morphology in Patients with Diabetic Macular Edema (DME) Randomized to Ranibizumab or Triamcino-lone Treatment. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256, 49-58. https://doi.org/10.1007/s00417-017-3828-1
|
[19]
|
Zur, D., Iglicki, M., Sala Puigdollers, A., et al. (2019) Disorgani-zation of Retinal Inner Layers as a Biomarker in Patients with Diabetic Macular Oedema Treated with Dexamethasone Implant. Acta Ophthalmologica, 98, e217-e223.
https://doi.org/10.1111/aos.14230
|
[20]
|
Chan, E.W., Eldeeb, M. and Sun, V. (2019) Disorganization of Retinal In-ner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion. Ophthalmology Retina, 3, 83-92.
https://doi.org/10.1016/j.oret.2018.07.008
|
[21]
|
Framme, C., Schweizer, P., Imesch, M., et al. (2012) Behavior of SD-OCT-Detected Hyperreflective Foci in the Retina of Anti-VEGF-Treated Patients with Diabetic Macular Edema. In-vestigative Ophthalmology & Visual Science, 53, 5814-5818. https://doi.org/10.1167/iovs.12-9950
|
[22]
|
Bonfiglio, V., Reibaldi, M., Pizzo, A., et al. (2019) Dexamethasone for Unresponsive Diabetic Macular Oedema: Optical Coherence Tomography Biomarkers. Acta Ophthalmologica (Oxford, England), 97, e540-e544.
https://doi.org/10.1111/aos.13935
|
[23]
|
Uji, A., Murakami, T., Nishijima, K., et al. (2012) Association between Hyperreflective Foci in the Outer Retina, Status of Photoreceptor Layer, and Visual Acuity in Diabetic Macular Edema. American Journal of Ophthalmology, 153, 710-717. https://doi.org/10.1016/j.ajo.2011.08.041
|
[24]
|
Castro-Navarro, V., Monferrer-Adsuara, C. and Navarro-Palop, C. (2021) Effect of Dexamethasone Intravitreal Implant on Visual Acuity and Foveal Photoreceptor Integrity in Macular Edema Secondary to Retinal Vascular Disease. Ophthalmologica, 244, 83-92. https://doi.org/10.1159/000512195
|
[25]
|
Wirth, M.A., Wons, J., Freiberg, F.J., et al. (2018) Impact of Long-Term Intravitreal Anti-Vascular Endothelial Growth Factor on Preexisting Microstructural Alterations in Diabetic Macular Edema. Retina (Philadelphia, Pa.), 38, 1824-1829. https://doi.org/10.1097/IAE.0000000000001788
|
[26]
|
Seo, K.H., Yu, S., Kim, M., et al. (2016) Visual and Mor-phologic Outcomes of Intravitreal Ranibizumab for Diabetic Macular Edema Based on Optical Coherence Tomography Patterns. Retina (Philadelphia, Pa.), 36, 588-595.
https://doi.org/10.1097/IAE.0000000000000770
|
[27]
|
Iacono, P., Parodi, M.B., Scaramuzzi, M., et al. (2017) Morphological and Functional Changes in Recalcitrant Diabetic Macular Oedema after Intravitreal Dexamethasone Im-plant. British Journal of Ophthalmology, 101, 791-795.
https://doi.org/10.1136/bjophthalmol-2016-308726
|
[28]
|
Hatz, K., Ebneter, A., Tuerksever, C., et al. (2018) Re-peated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Ophthalmologica, 239, 205-214. https://doi.org/10.1159/000485852
|